Sugi Predict

Sugi Predict / Compounds / SCHEMBL5666232

SCHEMBL5666232

SCHEMBL5666232

N#Cc1cccc(NC(=O)c2ccccc2N)c1

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.72
▸ FADS1 O60427 3/20 0.59
▸ PTGS1 P23219 1/20 0.59
▸ GRM4 Q14833 1/20 0.59
▸ P2RX1 P51575 1/20 0.59
▸ HDAC1 Q13547 1/20 0.58
▸ NR1H4 Q96RI1 1/20 0.57
▸ GRM5 P41594 1/20 0.56
▸ RXFP1 Q9HBX9 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.55
▸ MAPT P10636 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ LMNA P02545 1/20 0.53
▸ EGLN1 Q9GZT9 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28806576 0.90 HTT (0.67) HTTGRM4P2RX1HDAC1NR1H4
SCHEMBL17744881 0.85 FADS1 (0.72) FADS1PTGS1P2RX1ALDH1A1MEN1
SCHEMBL12700379 0.84 HTT (1.00) HTTGRM4P2RX1NR1H4GRM5
SCHEMBL15290401 0.84 PTGS1 (0.60) HTTFADS1PTGS1P2RX1ALDH1A1
SCHEMBL29738182 0.83 HTT (0.72) HTTGRM4P2RX1HDAC1NR1H4
SCHEMBL28994973 0.83 HTT (0.72) HTTGRM4P2RX1HDAC1NR1H4
SCHEMBL2894248 0.83 HTT (0.72) HTTGRM4P2RX1NR1H4GRM5
SCHEMBL5532340 0.83 HTT (0.64) HTTGRM4P2RX1HDAC1NR1H4
SCHEMBL24110764 0.81 HTT (0.58) HTTFADS1GRM4P2RX1ALDH1A1
SCHEMBL22223504 0.81 HTT (0.73) HTTGRM4P2RX1NR1H4GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074112-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ 2006-04-06 — — US disclosed
US-7002022-B2 N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF NOVARTIS AG (CH) 2006-02-21 — — US disclosed
US-6878720-B2 VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2005-04-12 — — US disclosed
US-20040198782-A1 N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2004-10-07 — — US disclosed
EP-1007037-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2004-10-06 — — EP disclosed
CN-1152014-C N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors ��˹��ŵ�� 2004-06-02 — — CN disclosed
US-6677369-B2 CARBOXIMIDAMIDE DERIVATIVE ANTICOAGULANTS INHIBIT FACTOR XA ELI LILLY AND COMPANY 2004-01-13 — — US disclosed
US-20030195223-A1 An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates BEIGHT DOUGLAS WADE (US) 2003-10-16 — — US disclosed
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2003-04-03 — — US disclosed
US-6448277-B2 ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS NOVARTIS AG (CH) 2002-09-10 — — US disclosed
US-6417200-B1 BLOOD COAGULATION FACTOR XA IN MAMMALS ELI LILLY AND COMPANY 2002-07-09 — — US disclosed
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-02-14 — — US disclosed
CN-1331680-A N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-01-16 — — CN disclosed
EP-1007037-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-06-14 — — EP disclosed
WO-1999000127-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195223-A1 An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates F12, F11, F2 HTT 3496/4885FADS1 2803/4885PTGS1 1153/4885
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, NR2E3 HTT 1712/4885FADS1 3089/4885PTGS1 916/4885
US-20060074112-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NR2E3, AXL, FLT1 HTT 1263/4885FADS1 1717/4885PTGS1 1126/4885
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, KDR HTT 1586/4885FADS1 3125/4885PTGS1 826/4885
US-20040198782-A1 N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, NR2E3 HTT 1702/4885FADS1 3083/4885PTGS1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.